Pope E, Lara-Corrales I, Sibbald C, et al. - Findings demonstrate the noninferiority of oral nadolol to oral propranolol, suggesting that nadolol could serve as an efficacious as well as safe alternative to propranolol in the treatment of infants with infantile hemangiomas (IH).

• A double-blind noninferiority prospective study with a noninferiority margin of 10% was conducted to compare propranolol with nadolol in infants aged 1 to 6 months with problematic IH.

• Patients (n=71) were treated with oral propranolol (n=36) and nadolol (n=35) in escalating doses up to 2 mg/kg/d.

• For size and color, the difference in IH between groups by t test was 8.8 and 17.1, respectively, in favor of the nadolol group, showing that nadolol was noninferior to propranolol.

• A 2.4 higher coefficient of involution was noted with nadolol, vs propranolol, for each doubling of time unit (week).

• Similar safety was observed between the 2 interventions.